Abstract

Objective: Hydroxychloroquine paired with Azithromycin, Vitamin C, Vitamin D, and Zinc (HAZDPac), was used as a multidrug therapy method to treat COVID-19 illness and superimposed secondary bacterial pneumonia. Concerns have been raised though about such combinations regarding cardiac QTc interval prolongation and risks of arrhythmias, which we set out to address in this study. Design: We evaluated cardiac safety in a Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infections study, conducted by ProgenaBiome. Acutely ill patients with COVID-19 had QTc intervals recorded in an outpatient setting utilizing a continuously worn EKG monitor for the duration of the 10 days treatment.  QTc intervals were normally distributed.   Two-sample t-tests were used to measure any significant differences in QTc intervals between treatment and placebo groups. Results: Between June 2020 and June 2021, 118 COVID-19 patients were recruited and signed informed consent, of which 83 were enrolled for a Double-Blind Randomized Placebo-Controlled Trial. Of the 83, 52 patients were randomly assigned to receive HAZDPac treatment, and 31 patients to receive placebo. Overall, and in stratified analysis by gender, maximum QTc values of patients in the treatment arm were normal and no differences were observed when compared to maximum QTc values from patients in the placebo arm (p≥0.15). There were no adverse events related to HAZDPac treatment. Conclusion: We found that the outpatient treatment of COVID-19 patients with HAZDPac which includes Hydroxychloroquine and Azithromycin, was not associated with prolongation of QTc compared to placebo and QTc remained within normal range.

References

1. Kai-Wang To, K., Tak-Yin Tsang, O., Chik-Yan Yip, C., Chan, KH., Wu, TC., Man-Chun Chan, J, et al. Consistent detection of 2019 novel coronavirus in saliva. Clinical Infectious Diseases. 12 February 2020. ciaa149.
2. WHO. Transmission of SARS-CoV-2: implications for infection prevention precautions. 9 July 2020.
3. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med. 2021 Jan;174(1):69-79.
4. Lei ZN, Wu ZX, Dong S, Yang DH, Zhang L, Ke Z, Zou C, Chen ZS. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. Pharmacol Ther. 2020 Dec; 216:107672.
5. Bansal P, Goyal A, Cusick A 4th, Lahan S, Dhaliwal HS, Bhyan P, Bhattad PB, Aslam F, Ranka S, Dalia T, Chhabra L, Sanghavi D, Sonani B, Davis JM 3rd. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med. 2021 Dec;53(1):117-134.
6. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems [Internet]. FDA. 2020 [cited 2024 Jul 9]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or
7. Office of Surveillance and Epidemiology Review of Hydroxychloroquine and Chloroquine [Internet]. FDA. 2020 May [cited 2024 Jul 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/OSE%20Review_Hydroxychloroquine-Cholorquine%20-%2019May2020_Redacted.pdf
8. Nicholas J. Mercuro, PharmD. “QT Interval Prolongation and Hydroxychloroquine and Azithromycin in Hospitalized Patients With COVID-19.” JAMA Cardiology, JAMA Network, 1 Sept. 2020, jamanetwork.com/journals/jamacardiology/article-abstract/2765631.
9. Francis Bessière, MD. “Assessment of QT Intervals in a Case Series of Patients With COVID-19 Treated with Hydroxychloroquine Alone or in Combination with Azithromycin.” JAMA Cardiology, JAMA Network, 1 Sept. 2020, jamanetwork.com/journals/jamacardiology/fullarticle/2765633.
10. Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, Thompson M, Cingolani E, Cheng S, Marban E, Albert CM, Chugh SS. Experience with Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc. 2020 Jun 16;9(12):e017144.
11. Chorin E, Dai M, Shulman E, et al.. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. 2020;26(6):808–809
12. Chorin E, Wadhwani L, Magnani S, et al. . QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020;17(9):1425–1433
13. Saleh M, Gabriels J, Chang D, et al. The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythm Electrophysiol. 2020;13(6): e00866
14. Rezuş C, Moga VD, Ouatu A, Floria M. QT interval variations and mortality risk: is there any relationship?. Anatol J Cardiol. 2015;15(3):255-258.
15. El Kadri M, Al Falasi O, Ahmed R, Al Awadhi A, Altaha Z, Hillis A, Panikkaveetil B, Abdalla S, Ansel Benette H, Almubarak A, Saifuddin M, Alattar Y, Oulhaj A, AlKaabi S. Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study. BMJ Open. 2022 Feb 9;12(2):e051579.
16. Rubin GA, Desai AD, Chai Z, Wang A, Chen Q, Wang AS, Kemal C, Baksh H, Biviano A, Dizon JM, Yarmohammadi H, Ehlert F, Saluja D, Rubin DA, Morrow JP, Avula UMR, Berman JP, Kushnir A, Abrams MP, Hennessey JA, Elias P, Poterucha TJ, Uriel N, Kubin CJ, LaSota E, Zucker J, Sobieszczyk ME, Schwartz A, Garan H, Waase MP, Wan EY. Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic. JAMA Netw Open. 2021 Apr 1;4(4):e216842.
17. Lagier JC, Million M, Cortaredona S, Delorme L, Colson P, Fournier PE, Brouqui P, Raoult D, Parola P; IHU Task Force. Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. Ther Clin Risk Manag. 2022 May 31; 18:603-617.
18. Brouqui P, Million M, Parola P, Mccullough PA, Raoult D. Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients. New Microbes New Infect. 2023 Oct 30; 55:101188.
19. RECOVERY Collaborative Group; Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Nov 19;383(21):2030-2040.
20. WHO Solidarity Trial Consortium, Pan, H., Peto, R., Henao-Restrepo, A. M., Preziosi, M. P., Sathiyamoorthy, V., Abdool Karim, Q., Alejandria, M. M., Hernández García, C., Kieny, M. P., Malekzadeh, R., Murthy, S., Reddy, K. S., Roses Periago, M., Abi Hanna, P., Ader, F., Al-Bader, A. M., Alhasawi, A., Allum, E., Alotaibi, A., … Swaminathan, S. (2021). Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. The New England journal of medicine, 384(6), 497–511.
21. Axfors C, Schmitt AM, Janiaud P, Van't Hooft J, Abd-Elsalam S, Abdo EF, Abella BS, Akram J, Amaravadi RK, Angus DC, Arabi YM, Azhar S, Baden LR, Baker AW, Belkhir L, Benfield T, Berrevoets MAH, Chen CP, Chen TC, Cheng SH, Cheng CY, Chung WS, Cohen YZ, Cowan LN, Dalgard O, de Almeida E Val FF, de Lacerda MVG, de Melo GC, Derde L, Dubee V, Elfakir A, Gordon AC, Hernandez-Cardenas CM, Hills T, Hoepelman AIM, Huang YW, Igau B, Jin R, Jurado-Camacho F, Khan KS, Kremsner PG, Kreuels B, Kuo CY, Le T, Lin YC, Lin WP, Lin TH, Lyngbakken MN, McArthur C, McVerry BJ, Meza-Meneses P, Monteiro WM, Morpeth SC, Mourad A, Mulligan MJ, Murthy S, Naggie S, Narayanasamy S, Nichol A, Novack LA, O'Brien SM, Okeke NL, Perez L, Perez-Padilla R, Perrin L, Remigio-Luna A, Rivera-Martinez NE, Rockhold FW, Rodriguez-Llamazares S, Rolfe R, Rosa R, Røsjø H, Sampaio VS, Seto TB, Shahzad M, Soliman S, Stout JE, Thirion-Romero I, Troxel AB, Tseng TY, Turner NA, Ulrich RJ, Walsh SR, Webb SA, Weehuizen JM, Velinova M, Wong HL, Wrenn R, Zampieri FG, Zhong W, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 Apr 15;12(1):2349. doi: 10.1038/s41467-021-22446-z. Erratum in: Nat Commun. 2021 May 14;12(1):3001.
22. Pradelle A, Mainbourg S, Provencher S, Massy E, Grenet G, Lega JC. Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate. Biomed Pharmacother. 2024 Feb;171:116055.
23. Cersosimo A, Cimino G, Amore L, Calvi E, Pascariello G, Inciardi RM, Lombardi CM, Vizzardi E, Metra M. Cardiac biomarkers and mortality in COVID-19 infection: A review. Monaldi Arch Chest Dis. 2022 Jun 23;93(1).
24. Mazzanti, Andrea, et al. “Association of Hydroxychloroquine with QTc Interval in Patients With COVID-19.” Circulation, 5 June 2020, www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.048476.
25. Cubeddu LX. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr Cardiol Rev. 2016;12(2):141-154.